Chautauqua Capital Management, a division of Baird Asset Management, released its third-quarter 2025 investor letter for the Baird Chautauqua International and Global Growth Fund. Global equity markets performed well in the quarter, but the funds underperformed their benchmarks due to stock selection in key sectors.

Novo Nordisk A/S (NYSE:NVO) was highlighted in the investor letter for the third quarter of 2025. The pharmaceutical company saw a one-month return of 7.99% and shares lost 40.46% of their value over the last 52 weeks. On December 30, 2025, Novo Nordisk A/S closed at $51.22 per share.

In the third quarter 2025 investor letter, Baird Chautauqua International and Global Growth Fund discussed Novo Nordisk A/S (NYSE:NVO), noting lower-than-expected revenues, earnings, and guidance. The company also announced a CEO change, with concerns over supply and prescription trends.

Novo Nordisk A/S (NYSE:NVO) is not among the 30 Most Popular Stocks Among Hedge Funds. While 50 hedge fund portfolios held the stock at the end of the third quarter, there are concerns about downside risk. Some AI stocks may offer greater upside potential, especially in the current economic climate.

Read more at Yahoo Finance: Here’s Why Novo Nordisk (NVO) Traded Down in Q3